<table id="t13" width="90%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 13. Established and Other Potentially Significant Drug Interactions</caption>
<col align="left" valign="top" width="34%"></col>
<col align="left" valign="top" width="33%"></col>
<col align="left" valign="top" width="33%"></col>
<thead>
<tr>
<th stylecode="Lrule Rrule">Concomitant Drug</th>
<th stylecode="Rrule">Effect on Concentration of Lamotrigine or Concomitant Drug</th>
<th stylecode="Rrule">Clinical Comment</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="3">↓= Decreased (induces lamotrigine gluronidation).</td>
</tr>
<tr>
<td align="left" colspan="3">↑= Increased (inhibits lamotrigine glucuronidation).</td>
</tr>
<tr>
<td align="left" colspan="3">?= Conflicting data.</td>
</tr>
</tfoot>
<tbody>
<tr>
<td rowspan="2" stylecode="Lrule Rrule Botrule">Estrogen-containing oral contraceptive preparations containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel</td>
<td stylecode="Rrule">↓ lamotrigine</td>
<td stylecode="Rrule">Decreased lamotrigine levels approximately 50%.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule">↓ levonorgestrel </td>
<td stylecode="Rrule">Decrease in levonorgestrel component by 19%.</td>
</tr>
<tr>
<td rowspan="2" stylecode="Lrule Rrule Botrule">Carbamazepine (CBZ) and CBZ epoxide</td>
<td stylecode="Rrule">↓ lamotrigine </td>
<td stylecode="Rrule">Addition of carbamazepine decreases lamotrigine concentration approximately 40%.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">? CBZ epoxide </td>
<td stylecode="Rrule">May increase CBZ epoxide levels.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Phenobarbital/Primidone </td>
<td stylecode="Rrule">↓ lamotrigine </td>
<td stylecode="Rrule">Decreased lamotrigine concentration approximately 40%.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Phenytoin (PHT) </td>
<td stylecode="Rrule">↓ lamotrigine </td>
<td stylecode="Rrule">Decreased lamotrigine concentration approximately 40%.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Rifampin</td>
<td stylecode="Rrule">↓ lamotrigine </td>
<td stylecode="Rrule">Decreased lamotrigine AUC approximately 40%.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Valproate </td>
<td stylecode="Rrule">↑ lamotrigine </td>
<td stylecode="Rrule">Increased lamotrigine concentrations slightly more than 2-fold.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule">? valproate </td>
<td stylecode="Rrule">Decreased valproate concentrations an average of 25% over a 3-week period then stabilized in healthy volunteers; no change in controlled clinical trials in epilepsy patients.</td>
</tr>
</tbody>
</table>